By Evans Matthews
Postpartum hemorrhage (PPH) – defined as excessive bleeding after childbirth, remains the leading cause of maternal mortality worldwide, claiming tens of thousands of lives each year. Despite being largely preventable and treatable, it continues to expose deep inequities in global health systems, particularly in low-and-middle-income countries where access to essential medicines is inconsistent and delayed.
“Postpartum hemorrhage is the most dangerous childbirth complication because it can escalate rapidly,” noted a World Health Organization (WHO) maternal health official in a recent guideline update. “With timely intervention, most deaths are preventable.”
At the heart of PPH management are a small group of uterotonic medicines – most notably oxytocin, misoprostol, and tranexamic acid. Oxytocin, administered via injection, is considered the gold standard for preventing and treating uterine atony, the most common cause of PPH. However, its effectiveness depends on strict cold-chain storage, which is often unreliable in rural or resource-constrained settings. Where refrigeration is unavailable, misoprostol, a heat-stable oral tablet, becomes a critical alternative.
“Misoprostol has transformed childbirth care in low-resource environments because it does not require refrigeration or advanced equipment,” explains Dr. Amina Yusuf, a maternal health specialist based in West Africa. “But availability does not always translate into access.”
Indeed, the global distribution of these medicines reveals a troubling gap between policy and practice. While WHO guidelines recommend uterotonics for all births as part of active management of the third stage of labour, stock-outs, poor procurement systems, and weak supply chains frequently interrupt delivery at the point of care. In many district hospitals and rural clinics, health workers are forced to improvise or delay treatment – often with fatal consequences.
Recent global assessments show that uterotonics are widely recognized as essential medicines, yet their quality and availability remain inconsistent across regions. Studies in several low-income countries have found that a significant proportion of oxytocin samples fail quality testing due to poor storage or supply chain degradation, reducing their effectiveness when urgently needed.
The problem is compounded by inequitable distribution systems. Urban tertiary hospitals may have consistent access to life-saving drugs, while rural health posts – where most births occur in high-burden countries often operate with minimal supplies. This disparity creates a dangerous delay in response time, which is critical given that severe PPH can become life-threatening within minutes.
Tranexamic acid (TXA), an antifibrinolytic agent, has also emerged as a vital adjunct therapy, reducing death from bleeding when administered early. Yet, like other emergency obstetric medicines, its integration into national essential medicine lists does not always guarantee its presence in delivery rooms.
Experts argue that the challenge is no longer scientific knowledge, but systems delivery. “We already have effective medicines,” says Professor Elena Rodriguez, a global obstetric researcher. “The real question is why women are still dying from a condition we know how to treat.”
Solutions are increasingly focused on strengthening supply chains, training frontline health workers, and decentralizing access to essential drugs. Innovations such as heat-stable uterotonics, pre-packed emergency obstetric kits, and community-level distribution of misoprostol are showing promise in bridging the gap.
Yet financing and governance remain critical barriers. Without sustained investment in procurement systems, storage infrastructure, and regulatory oversight, even the best medicines cannot reach the women who need them most.
As global health agencies push toward reducing maternal mortality under Sustainable Development Goals, tackling postpartum hemorrhage stands as both a medical and moral imperative. The tools exist; the challenge lies in ensuring they reach every birth, everywhere.
In the words of a midwife working in a rural referral hospital in East Africa: “No woman should die because a medicine was somewhere but not here, when she needed it most.”
English